Bracco's MultiHance market position in Germany - correction:
This article was originally published in Clinica
Executive Summary
In Clinica No 1136 (December 10 2004), we stated erroneously on page 20 that Bracco Diagnostics in the US (which is the Princeton, New Jersey branch of Milan, Italy-based Bracco SpA) claimed in a press briefing that its MultiHance MRI contrast agent, which provides improved visualisation of CNS lesions, was the market leader in Germany. What Bracco's head of WM medical affairs Dr Alberto Spinazzi actually said was "Bracco has two MR contrast agents approved in Germany (ProHance and MultiHance)-and together these two products enjoy a significant market share in Germany."